Primary Peptides Inc. is a clinical-stage, protein manipulation company established by leading neuroscientists from the Faculty of Medicine, University of British Columbia (UBC), Canada. We are focused on expanding the pool of druggable targets via protein manipulation to develop life transforming therapeutics for patients. Our pipeline consists of six, first-in-class peptide therapeutics for high unmet medical need indications in Cardiovascular Disease (CVD), Neurodegeneration, and Oncology.
Our discovery engine consists of three interrelated platform technologies enabling us to:

1) block the interactions of a pair of proteins through protein interference
2) stabilize and strengthen protein-protein interactions using molecular glues, and
3) degrade disease-causing proteins via the Lysosome or the Proteasome, which are the natural degradation machineries of the cell.

Our technologies enable us to pursue “undruggable” targets by manipulating how proteins interact and how they are degraded, offering advantages over other approaches, such as those using small molecules and antibodies.
We are a partnering company, and have signed two collaborations with Chinese companies for our two CVD assets for Greater China rights only. Rest of worlds rights are available for licensing. Our lead CVD asset is advancing into Phase 1b/2a in stroke patients later this year, while our second CVD asset is currently in IND enabling studies for the potential treatment of heart attack. We also have two preclinical assets being developed for Resistant Prostate Cancer and Liver Cancer for out-licensing.
Our two preclinical Neurodegeneration assets for the potential treatment of Parkinson’s Disease and ALS are currently for internal development.
We are seeking a Series A financing to advance our assets into clinical development and to further develop our platforms. This will be the first non-dilutive financing for the company.